Current Portfolio

Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.

Key Facts

Sector: Life Sciences
Country: United States
Fund: LSP Dementia Fund
Entry: 2025
Website: Rgenta Therapeutics

Responsible Partner

Cillian King

Partner

About

News

January 12, 2026
EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
January 12, 2026
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

Two Decades of Future Proofing Companies

What is a Private Equity Fund?

“Doing as We're Told Could've Cost EQT €50B”

Discover Our Latest Insights on ThinQ by EQT

EQT AB's Year-end Report 2025

Rgenta Therapeutics

Responsible Partner

Cillian King

News

EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases

EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

Do You Want to Know More?

Get in touch

Get in touch